Fig. 4
Vaccination of LMP1/pcDNA3.1 prevents LMP1-expressing tumor development in vivo. Upper panel, schedule of vaccination and tumor injection. Lower panel, percentage (%) of mice remained without tumor. C57BL/6 J mice were vaccinated weekly with either empty vector (control) or LMP1/pcDNA3.1 (vaccine) (n = 10) for 3 weeks. Subcutaneous injection of 1 × 105 LMP1-expressing TC-1 cells was given 3 weeks after the last dose of vaccination (D0). Tumor volumes were measured every 3 days. Re-challenge of 1 × 106 LMP1-expressing TC-1 cells was given to vaccine group on the 30th day. No tumor growth was observed until the 80th day. **, P < 0.01